ProMetic Life Sciences Inc. (TSE:PLI) Director Pierre Laurin sold 82,738 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of C$1.44, for a total value of C$119,142.72.

Pierre Laurin also recently made the following trade(s):

  • On Tuesday, September 12th, Pierre Laurin sold 82,738 shares of ProMetic Life Sciences stock. The shares were sold at an average price of C$1.45, for a total value of C$119,970.10.
  • On Thursday, September 7th, Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock. The shares were sold at an average price of C$1.45, for a total value of C$60,069.15.

Shares of ProMetic Life Sciences Inc. (TSE PLI) traded down 1.38% during mid-day trading on Friday, reaching $1.43. The company had a trading volume of 2,438,101 shares. The stock has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.87. The firm’s market capitalization is $1.01 billion. ProMetic Life Sciences Inc. has a 12-month low of $1.12 and a 12-month high of $3.24.

WARNING: “ProMetic Life Sciences Inc. (PLI) Director Pierre Laurin Sells 82,738 Shares” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/prometic-life-sciences-inc-pli-director-pierre-laurin-sells-82738-shares.html.

Several analysts recently commented on the company. TD Securities reduced their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a report on Wednesday, August 16th. Scotiabank reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a report on Friday, July 7th. National Bank Financial upped their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a report on Wednesday, August 30th. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a report on Wednesday, May 24th. Finally, Canaccord Genuity reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a report on Monday, June 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of C$3.60.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.